Cargando…
Protein kinase C in heart failure: a therapeutic target?
Heart failure (HF) afflicts about 5 million people and causes 300 000 deaths a year in the United States alone. An integral part of the pathogenesis of HF is cardiac remodelling, and the signalling events that regulate it are a subject of intense research. Cardiac remodelling is the sum of responses...
Autores principales: | Palaniyandi, Suresh Selvaraj, Sun, Lihan, Ferreira, Julio Cesar Batista, Mochly-Rosen, Daria |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2675930/ https://www.ncbi.nlm.nih.gov/pubmed/19168855 http://dx.doi.org/10.1093/cvr/cvp001 |
Ejemplares similares
-
PKCβII inhibition attenuates myocardial infarction induced heart failure and is associated with a reduction of fibrosis and pro-inflammatory responses
por: Palaniyandi, Suresh Selvaraj, et al.
Publicado: (2011) -
Protein Quality Control Disruption by PKCβII in Heart Failure; Rescue by the Selective PKCβII Inhibitor, βIIV5-3
por: Ferreira, Julio C. B., et al.
Publicado: (2012) -
Mitochondrial aldehyde dehydrogenase and cardiac diseases
por: Chen, Che-Hong, et al.
Publicado: (2010) -
New therapeutics to modulate mitochondrial dynamics and mitophagy in cardiac diseases
por: Disatnik, Marie-Hélène, et al.
Publicado: (2015) -
A Selective Inhibitor of Cardiac Troponin I Phosphorylation by Delta Protein Kinase C (δPKC) as a Treatment for Ischemia-Reperfusion Injury
por: Qvit, Nir, et al.
Publicado: (2022)